374 related articles for article (PubMed ID: 9523592)
1. Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists.
Sarre S; Vandeneede D; Ebinger G; Michotte Y
J Neurochem; 1998 Apr; 70(4):1730-9. PubMed ID: 9523592
[TBL] [Abstract][Full Text] [Related]
2. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic regulation of serotonin release in the substantia nigra of the freely moving rat using microdialysis.
Thorré K; Sarre S; Smolders I; Ebinger G; Michotte Y
Brain Res; 1998 Jun; 796(1-2):107-16. PubMed ID: 9689460
[TBL] [Abstract][Full Text] [Related]
4. Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists.
Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 1996 Feb; 296(3):247-60. PubMed ID: 8904076
[TBL] [Abstract][Full Text] [Related]
5. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
Mela F; Marti M; Bido S; Cenci MA; Morari M
Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
[TBL] [Abstract][Full Text] [Related]
6. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study.
Sarre S; Herregodts P; Deleu D; Devrieze A; De Klippel N; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):277-85. PubMed ID: 1407014
[TBL] [Abstract][Full Text] [Related]
8. The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis--II. Effects of dopamine D1 and D2 receptor agonists.
You ZB; Herrera-Marschitz M; Nylander I; Goiny M; O'Connor WT; Ungerstedt U; Terenius L
Neuroscience; 1994 Nov; 63(2):427-34. PubMed ID: 7891856
[TBL] [Abstract][Full Text] [Related]
9. Changes in extracellular levels of glutamate and aspartate in rat substantia nigra induced by dopamine receptor ligands: in vivo microdialysis studies.
Abarca J; Gysling K; Roth RH; Bustos G
Neurochem Res; 1995 Feb; 20(2):159-69. PubMed ID: 7783840
[TBL] [Abstract][Full Text] [Related]
10. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
Gołembiowska K; Dziubina A
Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
[TBL] [Abstract][Full Text] [Related]
11. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors.
Marti M; Mela F; Bianchi C; Beani L; Morari M
J Neurochem; 2002 Nov; 83(3):635-44. PubMed ID: 12390525
[TBL] [Abstract][Full Text] [Related]
12. Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 1998 Jul; 353(1):33-42. PubMed ID: 9721037
[TBL] [Abstract][Full Text] [Related]
13. The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors.
Santiago M; Westerink BH
Eur J Pharmacol; 1991 Oct; 204(1):79-85. PubMed ID: 1687125
[TBL] [Abstract][Full Text] [Related]
14. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
[TBL] [Abstract][Full Text] [Related]
15. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
Jonkers N; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Nov; 407(3):281-91. PubMed ID: 11068024
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Sarre S; De Klippel N; Herregodts P; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jul; 350(1):15-21. PubMed ID: 7935849
[TBL] [Abstract][Full Text] [Related]
17. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
18. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Biggs CS; Fisher A; Starr MS
Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
[TBL] [Abstract][Full Text] [Related]
19. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
[TBL] [Abstract][Full Text] [Related]
20. 5-HT4 receptor involvement in the serotonin-enhanced dopamine efflux from the substantia nigra of the freely moving rat: a microdialysis study.
Thorré K; Ebinger G; Michotte Y
Brain Res; 1998 Jun; 796(1-2):117-24. PubMed ID: 9689461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
